Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

The Company’s cash and cash equivalents are maintained in the following respective currencies as of December 31, 2018 and 2017:

 

 

As of

December 31, 

in CHF thousands 2018   2017
Cash and cash equivalents 156,462   124,377
Total 156,462   124,377
       
By currency      
CHF 126,218   103,272
EUR 11,471   3,658
USD 18,773   17,447
Total cash and cash equivalents 156,462   124,377

 

At the balance sheet dates, Company funds were held in CHF, EUR and USD currencies. As of December 31, 2018 and 2017, funds in EUR and USD were translated into CHF at a rate of 1.125 and 0.983 and 1.169 and 0.976, respectively for each currency and year.

 

The Company also has two deposits in escrow accounts totaling CHF 0.3 million and 0.1 million for the lease of the Company’s premises as of December 31, 2018 and 2017, respectively.

 

6.Prepaid expenses and accrued income

 

 

As of

December 31, 

in CHF thousands 2018   2017
Prepaid expenses 2,364   1,440
Accrued income 3,667   2,799
Total 6,031   4,239

 

The prepaid expenses relate mainly to research contracts with down-payments at contract signature and the related activities will start or continue into 2019.

 

Accrued income consists of CHF 1.2 million as of December 31, 2018 associated with our Biogen collaboration and CHF 2.1 million associated with our Janssen collaboration (see Note 11). This amount represents 33.5% and 56.8%, respectively of our total accrued income as of December 31, 2018.

 

7.Other current receivables

 

 

As of

December 31, 

in CHF thousands 2018   2017
Other receivables 17   691
Swiss VAT 209   112
Withholding tax 10   115
Total 236   918

 

The maturity of these assets is less than three months. The Company considers the counterparty risk as low and the carrying amount of these receivables is considered to approximate their fair value.

 

 F-17


© AC Immune 2015